menu
    • menu
    [{"orgOrder":0,"company":"Eleusis","sponsor":"Beckley Psytech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Psilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eleusis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eleusis \/ Beckley Psytech","highestDevelopmentStatusID":"6","companyTruncated":"Eleusis \/ Beckley Psytech"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deuterated N,N-dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Small Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Small Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"Neurocentrx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Beckley Psytech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beckley Psytech \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DSP-2342","moa":"5-HT2A\/5-HT7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exscientia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Inapplicable"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"C4X Discovery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"C4X Discovery \/ Indivior","highestDevelopmentStatusID":"6","companyTruncated":"C4X Discovery \/ Indivior"}]

    Find Psychiatry/Psychology Drugs in Phase I Clinical Development in UNITED KINGDOM

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurocentrx Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Neurocentrx Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurocentrx Provides Update on Clinical Progress of Lead Programme, Keticap®, an Oral Ketamine Formulation fo...

                            Details : Keticap® is an oral immediate-release ketamine formulation intended for the treatment of mood disorders such as treatment-resistant depression (TRD) and bipolar depression.

                            Product Name : Keticap

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 05, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurocentrx Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Neurocentrx Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Pr...

                            Details : Keticap, is a novel oral ketamine immediate-release (IR) formulation to treat major mental health conditions, including treatment-resistant depression.

                            Product Name : Keticap

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 24, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Small Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Small Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Small Pharma's Phase I Study Exploring Intramuscular Administration of SPL026

                            Details : SPL026, is a proprietary synthetic formulation of N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine being developed as a supportive therapy for patients with mental health conditions or major depressive disorder.

                            Product Name : SPL026

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exscientia

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Exscientia

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DSP-2342

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

                            Details : DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease.

                            Product Name : DSP-2342

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 15, 2023

                            Lead Product(s) : DSP-2342

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Small Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Small Pharma

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deuterated N,N-dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

                            Details : SPL028, is formulation of deuterated N, N-dimethyltryptamine which offers a similar safety and pharmacological profile to its lead candidate SPL026 or DMT.

                            Product Name : SPL028

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2023

                            Lead Product(s) : Deuterated N,N-dimethyltryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            C4X Discovery

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            C4X Discovery

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INDV-2000

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Indivior

                            Deal Size : $20.4 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for £15.95m

                            Details : Through the divestment, Indivior gains the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, INDV-2000 (C4X_3256) for substance use disorder.

                            Product Name : INDV-2000

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2023

                            Lead Product(s) : INDV-2000

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Indivior

                            Deal Size : $20.4 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Beckley Psytech

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin Benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Form...

                            Details : BPL-003, a synthetic intranasal formulation of 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), which is under development for Treatment Resistant Depression and Alcohol Use Disorder.

                            Product Name : BPL-003

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            November 15, 2022

                            Lead Product(s) : Mebufotenin Benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eleusis

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Eleusis

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocin

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Beckley Psytech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

                            Details : The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.

                            Product Name : ELE-101

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Psilocin

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Beckley Psytech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Beckley Psytech

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Beckley Psytech

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebufotenin Benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Beckley Psytech to Present at 32nd Annual Oppenheimer Healthcare Conference

                            Details : Phase 1 trial is evaluating the safety and tolerability of a novel formulation of intranasal 5-methoxy-N,N-dimethyltryptamine, in treatment resistant depression (TRD) and other neuropsychiatric indications.

                            Product Name : BPL-003

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 03, 2022

                            Lead Product(s) : Mebufotenin Benzoate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            LB Pharmaceuticals

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            LB Pharmaceuticals

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N-Methyl Amisulpride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LB Announces Publication of Phase 1 Clinical Study of LB-102

                            Details : LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D2/D3 and 5HT7 receptors (critical to the treatment of schizo...

                            Product Name : LB-102

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 19, 2022

                            Lead Product(s) : N-Methyl Amisulpride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth